Pfizer’s pending acquisition of Arena Pharma includes Olorinab, a candidate that acts with the cannabinoid type 2 receptor to treat gastrointestinal disorders.
Pfizer’s pending acquisition of Arena Pharma includes Olorinab, a candidate that acts with the cannabinoid type 2 receptor to treat gastrointestinal disorders.
Fintedex delivers real-time news about the financial industry: feature stories, industry developments, opinions plus the latest on people and trends.
© 2021 Fintedex.